ePrints

Novel bile acid therapeutics for the treatment of chronic liver diseases

Lookup NU author(s): Dr Vinod Hegade, Dr Richard Speight, Rachel Etherington, Professor David Jones

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Recent developments in understanding the role of bile acids (BAs) as signalling molecules in human metabolism and inflammation have opened new avenues in the field of hepatology research. BAs are no longer considered as simple molecules helping in fat digestion but as agents with real therapeutic value in treating complex autoimmune and metabolic liver diseases. BAs and their receptors such as farnesoid X receptor, transmembrane G protein-coupled receptor 5 and peroxisome proliferator-activated receptor have been identified as novel targets for drug development. Some of these novel pharmaceuticals are already in clinical evaluation with the most advanced drugs having reached phase III trials. Chronic liver diseases such as primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic fatty liver disease, for which there is no or limited pharmacotherapy, are most likely to gain from these developments. In this review we discuss recent and the most relevant basic and clinical research findings related to BAs and their implications for novel therapy for chronic liver diseases.

Publication metadata

Author(s): Hegade VS, Speight RA, Etherington RE, Jones DEJ

Publication type: Review

Publication status: Published

Journal: Therapeutic advances in gastroentology

Year: 2016

Volume: 9

Issue: 3

Pages: 376-391

Print publication date: 01/05/2016

Acceptance date: 01/01/1900

ISSN (print): 1756-283X

ISSN (electronic): 1756-2848

Publisher: SAGE PUBLICATIONS LTD

URL: http://dx.doi.org/10.1177/1756283X16630712

DOI: 10.1177/1756283X16630712

Share